[go: up one dir, main page]

MX2024014319A - Anticuerpos anti-bcma unicamente de cadena pesada - Google Patents

Anticuerpos anti-bcma unicamente de cadena pesada

Info

Publication number
MX2024014319A
MX2024014319A MX2024014319A MX2024014319A MX2024014319A MX 2024014319 A MX2024014319 A MX 2024014319A MX 2024014319 A MX2024014319 A MX 2024014319A MX 2024014319 A MX2024014319 A MX 2024014319A MX 2024014319 A MX2024014319 A MX 2024014319A
Authority
MX
Mexico
Prior art keywords
antibodies
heavy chain
bcma
bcma heavy
compositions
Prior art date
Application number
MX2024014319A
Other languages
English (en)
Inventor
Nathan Trinklein
Shelley Force Aldred
Starlynn Clarke
Wim Van Schooten
Original Assignee
Teneoone Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneoone Inc filed Critical Teneoone Inc
Publication of MX2024014319A publication Critical patent/MX2024014319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos anti-BCMA únicamente de cadena pesada (UniAb) junto con métodos para elaborar dichos anticuerpos, composiciones, incluidas las composiciones farmacéuticas que comprenden dichos anticuerpos, y su uso para tratar trastornos de linfocitos B caracterizados por la expresión de BCMA.
MX2024014319A 2017-06-20 2019-12-18 Anticuerpos anti-bcma unicamente de cadena pesada MX2024014319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522295P 2017-06-20 2017-06-20
PCT/US2018/038506 WO2018237006A1 (en) 2017-06-20 2018-06-20 Anti-bcma heavy chain-only antibodies

Publications (1)

Publication Number Publication Date
MX2024014319A true MX2024014319A (es) 2024-12-06

Family

ID=62875335

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015563A MX2019015563A (es) 2017-06-20 2018-06-20 Anticuerpos anti-bcma unicamente de cadena pesada.
MX2024014319A MX2024014319A (es) 2017-06-20 2019-12-18 Anticuerpos anti-bcma unicamente de cadena pesada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019015563A MX2019015563A (es) 2017-06-20 2018-06-20 Anticuerpos anti-bcma unicamente de cadena pesada.

Country Status (9)

Country Link
US (2) US11427642B2 (es)
EP (1) EP3642236A1 (es)
JP (3) JP7240335B2 (es)
CN (3) CN117567624A (es)
AU (2) AU2018288803B2 (es)
BR (1) BR112019026803A2 (es)
CA (1) CA3065951A1 (es)
MX (2) MX2019015563A (es)
WO (1) WO2018237006A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018016404A (es) 2016-06-21 2019-10-15 Teneobio Inc Anticuerpos de union a cd3.
KR20190052006A (ko) 2016-08-24 2019-05-15 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
KR20250004936A (ko) 2016-12-21 2025-01-08 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
KR102742528B1 (ko) * 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
CN111094345B (zh) * 2017-06-30 2023-10-27 美国卫生和人力服务部 具有人结构域的抗b细胞成熟抗原嵌合抗原受体
UA128757C2 (uk) 2017-12-22 2024-10-16 Тенеобіо, Інк. Антитіла, які містять тільки важкі ланцюги, що зв'язуються з cd22
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
CA3101069A1 (en) 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
JOP20210323A1 (ar) 2019-06-14 2023-01-30 Teneobio Inc ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
EP4077398A4 (en) * 2019-12-16 2024-04-10 Legend Biotech Ireland Limited SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
MX2022013453A (es) 2020-04-29 2022-11-16 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
UY40003A (es) 2020-04-29 2023-03-31 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
WO2022006316A1 (en) * 2020-06-30 2022-01-06 Teneobio, Inc. Multi-specific antibodies binding to bcma
WO2023068382A2 (en) * 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
JP4253826B2 (ja) 1999-09-07 2009-04-15 カシオ計算機株式会社 画像読取装置
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
AU2005263994B2 (en) 2004-07-22 2011-03-24 Roger Kingdon Craig Binding molecules
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100209437A1 (en) 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
WO2007066109A1 (en) 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2008016431A2 (en) 2006-07-29 2008-02-07 Robert Lamar Bjork Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
EP3382022A1 (en) 2007-06-01 2018-10-03 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20120039870A9 (en) * 2007-09-07 2012-02-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2738565C (en) 2008-10-01 2023-10-10 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
MX2011009430A (es) 2009-03-10 2011-11-18 Biogen Idec Inc Anticuerpos anti-bcma.
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
PL2505654T5 (pl) 2010-02-08 2020-11-30 Regeneron Pharmaceuticals, Inc. Mysz ze wspólnym łańcuchem lekkim
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
HUE063461T2 (hu) 2011-05-27 2024-01-28 Glaxo Group Ltd BCMA (CD269/TNFRSF17)-kötõ fehérjék
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1207398A1 (en) 2012-04-20 2016-01-29 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP6694712B2 (ja) * 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
FI3653049T3 (fi) 2012-12-14 2023-11-02 Omniab Inc Polynukleotidit, jotka koodaavat jyrsijän vasta-aineita, joissa on ihmisen idiotyyppejä, ja näitä käsittävät eläimet
CN104968682A (zh) 2013-02-05 2015-10-07 英格玛布股份公司 针对CD3ε和BCMA的双特异性抗体
KR20160090308A (ko) 2013-11-04 2016-07-29 그렌마크 파머수티칼스 에스. 아. T 세포 재표적 이형-이량체 면역글로불린의 생산
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
LT3122781T (lt) 2014-03-28 2020-03-25 Xencor, Inc. Bispecifiniai antikūnai, kurie jungiasi prie cd38 ir cd3
EP3172237A2 (en) * 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
PT3063173T (pt) 2014-07-31 2020-10-20 Sanofi Sa Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
CN107002092A (zh) 2014-10-22 2017-08-01 克雷森多生物制剂有限公司 转基因小鼠
CA2968162A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3230321B1 (en) 2014-12-12 2019-08-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
WO2016187546A1 (en) 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
HUE050556T2 (hu) 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
AU2016352676A1 (en) 2015-11-10 2018-05-31 University Medical Center Hamburg - Eppendorf ANTIGEN-binding polypeptides directed against CD38
MX2018016404A (es) 2016-06-21 2019-10-15 Teneobio Inc Anticuerpos de union a cd3.
KR20190052006A (ko) 2016-08-24 2019-05-15 테네오바이오, 인코포레이티드 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물
UA126384C2 (uk) * 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
MX2019004621A (es) 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
KR20250004936A (ko) 2016-12-21 2025-01-08 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
KR102742528B1 (ko) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN111094345B (zh) 2017-06-30 2023-10-27 美国卫生和人力服务部 具有人结构域的抗b细胞成熟抗原嵌合抗原受体
UA128757C2 (uk) 2017-12-22 2024-10-16 Тенеобіо, Інк. Антитіла, які містять тільки важкі ланцюги, що зв'язуються з cd22
RU2020124623A (ru) 2017-12-27 2022-01-27 Тенеобио, Инк. Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
CA3101340A1 (en) 2018-05-24 2019-11-28 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
CA3101069A1 (en) 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
BR112021004680A2 (pt) 2018-09-21 2021-08-31 Teneobio, Inc. Métodos para purificar anticorpos multiespecíficos heterodiméricos
EP3870611A1 (en) 2018-10-26 2021-09-01 TeneoBio, Inc. Heavy chain antibodies binding to cd38
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
JOP20210323A1 (ar) 2019-06-14 2023-01-30 Teneobio Inc ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
MX2022013453A (es) 2020-04-29 2022-11-16 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
BR112022024483A2 (pt) 2020-04-29 2023-02-07 Teneoone Inc Métodos para tratar mieloma múltiplo
UY40003A (es) 2020-04-29 2023-03-31 Teneobio Inc Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
WO2022006316A1 (en) 2020-06-30 2022-01-06 Teneobio, Inc. Multi-specific antibodies binding to bcma

Also Published As

Publication number Publication date
JP2023071876A (ja) 2023-05-23
CA3065951A1 (en) 2018-12-27
AU2018288803A1 (en) 2020-02-06
US20200157232A1 (en) 2020-05-21
US20230060847A1 (en) 2023-03-02
CN110945026A (zh) 2020-03-31
CN110945026B (zh) 2024-03-19
MX2019015563A (es) 2020-07-28
JP2024084776A (ja) 2024-06-25
EP3642236A1 (en) 2020-04-29
WO2018237006A1 (en) 2018-12-27
CN118146370A (zh) 2024-06-07
AU2025203751A1 (en) 2025-06-19
AU2018288803B2 (en) 2025-02-27
JP7240335B2 (ja) 2023-03-15
JP2020524000A (ja) 2020-08-13
CN117567624A (zh) 2024-02-20
US11427642B2 (en) 2022-08-30
BR112019026803A2 (pt) 2020-06-30
JP7465382B2 (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
ZA202311311B (en) Anti-bcma heavy chain-only antibodies
MX2024014319A (es) Anticuerpos anti-bcma unicamente de cadena pesada
ZA201903985B (en) Anti-bcma heavy chain-only antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MY191581A (en) Anti-pd-1 antibodies
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
NZ737399A (en) Ccr2 modulators
EP4516319A3 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MY192927A (en) Fused bicyclic compounds for the treatment of disease
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
PH12018500379B1 (en) Biopharmaceutical compositions
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GEP20186893B (en) Pyrazines modulators of gpr6
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.